<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25487642</article-id>
      <article-id pub-id-type="pmc">4295483</article-id>
      <article-id pub-id-type="publisher-id">1851</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-379</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pediatric primary splenic angiosarcoma: an aggressive multidisciplinary approach to the oncologic management of a rare malignancy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Serrano</surname>
            <given-names>Oscar K</given-names>
          </name>
          <address>
            <email>oserrano@montefiore.org</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Knapp</surname>
            <given-names>Esther</given-names>
          </name>
          <address>
            <email>eknapp@montefiore.org</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Kevin</given-names>
          </name>
          <address>
            <email>kevin.huang@med.einstein.yu.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baran</surname>
            <given-names>Galina</given-names>
          </name>
          <address>
            <email>gbaran55@aol.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Statter</surname>
            <given-names>Mindy</given-names>
          </name>
          <address>
            <email>mstatter@montefiore.org</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McClain</surname>
            <given-names>Danielle</given-names>
          </name>
          <address>
            <email>damcclai@montefiore.org</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gill</surname>
            <given-names>Jonathan</given-names>
          </name>
          <address>
            <email>jgill@montefiore.org</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <aff id="Aff2"><label/>Division of Pediatric Surgery, Department of Surgery, Children&#x2019;s Hospital at Montefiore Medical Center, 3415 Bainbridge Avenue, New York, NY 10467 USA </aff>
        <aff id="Aff3"><label/>Albert Einstein College of Medicine, 1300 Morris Park Avenue, New York, NY 10461 USA </aff>
        <aff id="Aff4"><label/>Division of Hematology-Oncology, Children&#x2019;s Hospital at Montefiore Medical Center, 3415 Bainbridge Avenue, New York, NY 10467 USA </aff>
        <aff id="Aff5"><label/>Department of Radiology, Bronx-Lebanon Hospital, 1650 Grand Concourse, New York, NY 10457 USA </aff>
        <aff id="Aff6"><label/>Department of Pathology, Montefiore Medical Center, 111 East 210th Street, New York, NY 10467 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <elocation-id>379</elocation-id>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Serrano et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Primary splenic angiosarcoma is an extremely rare and aggressive neoplasm of the vasculature. Uniformly, primary splenic angiosarcoma is a fatal disease despite early diagnosis and treatment. Only patients with localized disease amenable to surgical resection achieve long-term, disease-free survival. We present a review of the literature and report a case of a 3-year-old girl with metastatic primary splenic angiosarcoma who was offered aggressive surgical and medical treatment with curative intent despite her advanced presentation.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Angiosarcoma</kwd>
        <kwd>Spleen</kwd>
        <kwd>Pediatric</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Primary splenic angiosarcoma (PSA) is an extremely rare and aggressive neoplasm of the vasculature that occurs in adults and children. Uniformly, PSA is a fatal disease despite early diagnosis and treatment. To date, only patients with localized disease amenable to surgical resection are likely to achieve long-term, disease-free survival. In this review, we summarize the literature and report a case of a 3-year-old girl with metastatic PSA who was offered aggressive surgical and medical treatment with curative intent despite her advanced presentation. Following splenectomy, our patient was given a gemcitabine-docetaxel chemotherapeutic regimen, which has never been described before in children with PSA. This treatment regimen achieved a partial response and was followed by liver metastasectomy. This enabled us to render her free of any gross disease and allowed her to undergo the living-related liver transplantation evaluation as a viable curative option.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>We report on a previously healthy 3-year-old girl who presented with complaints of abdominal pain and distention, and decreased oral intake in the setting of high fevers. On physical examination, she was found to have massive splenomegaly. Her laboratory work-up was significant for anemia and mild thrombocytopenia. An abdominal X-ray showed a markedly enlarged spleen with displacement of bowel and an abdominal ultrasound revealed several hyperechoic nodules in an enlarged spleen. This prompted magnetic resonance imaging (MRI) of the abdomen which showed massive splenomegaly with central hemorrhage and multiple nodular lesions in the liver (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).Fearing splenic rupture in the setting of hemodynamic decompensation, an emergent splenectomy was performed. Intraoperatively, she was noted to have a massively enlarged multinodular spleen, gross nodular lesions on her liver, a minimal amount of ascites, and no evidence of further organ involvement. Pathologic examination revealed an enlarged, nodular spleen with a central hemorrhagic component (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Histologic examination revealed findings consistent with high-grade angiosarcoma (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) and the diagnosis of PSA was confirmed with additional stains for smooth muscle actin and CD34 (Figure&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Cytology from the peritoneal fluid was negative for malignant cells.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Axial pre- and post-contrast T1-weighted magnetic resonance images.</bold> The pre-contrast T1-weighted image demonstrates an enlarged spleen with a small area of high signal in the periphery, suggestive of focal hemorrhage. Pre-contrast T1-weighted images also demonstrate three small hypointense hepatic lesions in both lobes of the liver, which show avid enhancement following administration of intravenous contrast. Bottom. Post-contrast T1-weighted images of the spleen demonstrate nearly complete replacement of the spleen by the tumor and by multiple areas of necrosis.</p></caption><graphic xlink:href="12957_2014_1851_Fig1_HTML" id="d30e341"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Gross multinodular spleen specimen.</bold> The tumor is not a well circumscribed mass but rather a diffuse process replacing the entire spleen, therefore a definitive size is difficult to determine. The spleen weighed 540&#xA0;g and measured 17&#x2009;&#xD7;&#x2009;12&#x2009;&#xD7;&#x2009;45&#xA0;cm in overall dimensions.</p></caption><graphic xlink:href="12957_2014_1851_Fig2_HTML" id="d30e353"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Histologic examination revealed findings consistent with high-grade angiosarcoma. (A)</bold> Medium power view showing anastomosing vascular channels lined by highly atypical cells (200&#xD7;). <bold>(B)</bold> Medium power view showing numerous mitoses with one highlighted by the arrow (200&#xD7;).</p></caption><graphic xlink:href="12957_2014_1851_Fig3_HTML" id="d30e369"/></fig><fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>The diagnosis of primary splenic angiosarcoma was confirmed with additional stains for smooth muscle actin and CD34. (A)</bold> Low power view of strongly positive CD34 stain (100&#xD7;). <bold>(B)</bold> Low power view of smooth muscle actin stain, which highlights the vascular architecture (100&#xD7;).</p></caption><graphic xlink:href="12957_2014_1851_Fig4_HTML" id="d30e384"/></fig></p>
      <p>Her post-operative work-up included positron emission tomography-computed tomography (PET/CT), which revealed fluorodeoxyglucose-avid disease exclusive to the liver (Figure&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Given the diffuse, nodular infiltration of the liver, her disease was deemed unresectable and she was offered chemotherapy. She was treated with a total of eight cycles of gemcitabine and docetaxel as described by Rapkin and colleagues [<xref ref-type="bibr" rid="CR1">1</xref>]. A repeat MRI after cycle 5 demonstrated a decrease in the size and number of the liver lesions. Five months after her splenectomy, she underwent a wedge liver biopsy to evaluate her metastatic disease. The pathology revealed extensive necrosis with foci of viable tumor cells consistent with a partial response to chemotherapy (Figure&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Positron emission tomography-computed tomography (posterior view) confirms diffuse small areas of uptake in the hepatic parenchyma consistent with metastatic disease to the liver.</bold>
</p></caption><graphic xlink:href="12957_2014_1851_Fig5_HTML" id="d30e407"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>Histologic examination of wedge liver biopsy. (A)</bold> Low power (2&#xD7;) view of metastatic liver lesion showing area of necrosis and hemosiderin with a small focus of viable tumor remaining at the periphery of the specimen. <bold>(B)</bold> Low power (4&#xD7;) view showing area of necrosis and hemosiderin with no viable tumor remaining.</p></caption><graphic xlink:href="12957_2014_1851_Fig6_HTML" id="d30e422"/></fig></p>
      <p>After extensive discussion in our multidisciplinary tumor board, and given her favorable response to chemotherapy, the option of living-related liver transplantation was made available to the family as a means to render the patient disease-free. However, during the transplant evaluation time period, the patient had clinical deterioration and was admitted to the hospital with worsening abdominal pain and distention. She was found to have bilateral pleural effusions and extensive ascites. Liver failure rapidly ensued and, within days of her admission, her family opted for comfort care measures. She died shortly thereafter.</p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>First described by Theodor Langhans in 1879 [<xref ref-type="bibr" rid="CR2">2</xref>], PSA is among the rarest forms of cancer with a reported incidence between 0.14 and 0.25 per million persons [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The median age of diagnosis is 63&#xA0;years old and, to date, only seven pediatric cases of PSA have been described in the literature (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. A number of environmental agents or predisposing conditions have been associated with the development of PSA in adults, including exposure to ionizing radiation [<xref ref-type="bibr" rid="CR10">10</xref>], prior chemotherapy for lymphoma [<xref ref-type="bibr" rid="CR12">12</xref>], or the presence of benign tumors of the spleen - namely hemangiomas or hemangioendotheliomas [<xref ref-type="bibr" rid="CR5">5</xref>]. However, given its scarce incidence, it is difficult to definitively isolate risk factors.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Published cases of pediatric primary splenic angiosarcoma</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Report</th><th>Age</th><th>Sex</th><th>Metastasis</th><th>Reported survival</th></tr></thead><tbody><tr><td>Alt <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR5">5</xref>]</td><td>14&#xA0;months</td><td>M</td><td>Liver, lung</td><td>3&#xA0;months</td></tr><tr><td>den Hoed <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR6">6</xref>]</td><td>2&#xA0;years</td><td>F</td><td>Liver</td><td>30&#xA0;months</td></tr><tr><td>Ferrara <italic>et al.</italic> (1955) [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td>15&#xA0;years</td><td>F</td><td>Liver</td><td/></tr><tr><td>Hsu <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR8">8</xref>]</td><td>7&#xA0;years</td><td>M</td><td>None</td><td>16&#xA0;years</td></tr><tr><td>Kren <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR9">9</xref>]</td><td>15&#xA0;years</td><td>M</td><td>Liver</td><td>&lt;1&#xA0;month</td></tr><tr><td>Serrano <italic>et al.</italic> (2014; present study)</td><td>3&#xA0;years</td><td>F</td><td>Liver</td><td>8&#xA0;months</td></tr><tr><td>Sordillo <italic>et al.</italic> (1983) [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td>12&#xA0;years</td><td>F</td><td>Liver, bone, bone marrow</td><td>&lt;1&#xA0;month</td></tr><tr><td>Wick <italic>et al.</italic>
[<xref ref-type="bibr" rid="CR11">11</xref>]</td><td>13&#xA0;years</td><td>M</td><td>Liver, bone, serosal surfaces, skin</td><td>10&#xA0;months</td></tr></tbody></table><table-wrap-foot><p>F, female; M, male.</p></table-wrap-foot></table-wrap></p>
      <p>To date, only two case series have been published that describe the pathologic behavior of PSA on a combined 68 adult patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, clinical and pathologic characteristics can be gleaned from these small studies. Patients commonly present with abdominal pain (83%) and splenomegaly (92%). Constitutional symptoms are not generally a characteristic of PSA, with only 40% of patients exhibiting weight loss, 10% experiencing fevers, and 5% complaining of fatigue. A small minority of patients (13%) will present with splenic rupture which is uniformly considered a grave prognostic factor given the high probability of widely disseminated disease. Hematologic analysis is also inconclusive. Over 90% of patients present with cytopenia, including anemia (49%), thrombocytopenia (25%), or pancytopenia (23%), while a small minority of patients exhibit leukocytosis (18%) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. It is unclear whether these features are direct manifestations of the disease or simply indirect correlations of splenomegaly.</p>
      <p>Histologically, angiosarcomas are rapidly proliferating, highly infiltrating anaplastic tumors that recur locally, spread widely, and have a propensity for rapid lymph node and systemic dissemination [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. They arise from splenic vascular endothelium and mesenchymal-derived elongated endothelial cells lining the spleen&#x2019;s spongy sinusoidal network [<xref ref-type="bibr" rid="CR13">13</xref>]. Their immediate access to the reticuloendothelial system and their location of origin may in part explain the aggressive nature and behavior of PSA. On gross examination, spleens often weigh &gt;1,000 grams [<xref ref-type="bibr" rid="CR3">3</xref>]. Macroscopic examination reveals a diffuse replacement of splenic parenchyma by tumor [<xref ref-type="bibr" rid="CR13">13</xref>]. Microscopically, PSA has a characteristic vascular channel formation with carcomatous stroma [<xref ref-type="bibr" rid="CR14">14</xref>]. The tumor itself consists of disorganized anastomosing vascular channels lined by large, atypical endothelial cells with significant irregular, hyperchromatic nuclei (Figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. Several reports of PSA have described massive splenic calcifications as a feature of the disease [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]; however, calcifications can also be found in benign processes, making it a nonspecific characteristic for malignancy.</p>
      <p>Radiologic features of PSA can range from ambiguous lesions to highly aggressive-appearing tumors in the spleen, often with concomitant metastases at the time of diagnosis [<xref ref-type="bibr" rid="CR17">17</xref>]. Ultrasound findings of PSA are nonspecific in the majority of cases, but it is usually the first diagnostic test performed in children. The most common ultrasound findings are splenomegaly, splenic heterogeneity, and poorly defined solid and cystic lesions [<xref ref-type="bibr" rid="CR17">17</xref>]. Areas of hemorrhage and necrosis within the tumor are frequently seen as cystic lesions. Increased Doppler flow may be seen in the more solid echogenic portions of the tumor [<xref ref-type="bibr" rid="CR18">18</xref>]. On CT, the most common appearance is that of a heterogeneous lesion with areas of low density and necrotic degeneration [<xref ref-type="bibr" rid="CR17">17</xref>]. Non-contrast CT images may demonstrate areas of high density from recent hemorrhage or calcifications from the hemosiderin deposits [<xref ref-type="bibr" rid="CR19">19</xref>]. Images performed with intravenous contrast show marked heterogeneous enhancement, necrosis, and hemorrhage. CT evidence of dense ascites is highly suggestive of the spontaneous hemorrhage from splenic rupture. Hypervascular metastatic deposits have been reported in the literature [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Most of these are found in the liver, but they have also been described in the lungs, bones and lymphatic organs. The MRI appearance of PSA depends on the extent of the hemorrhage and necrosis in the tumor. Areas of increased and decreased signal intensity may be seen on images obtained with both T1- and T2-weighted pulse sequences depending on the presence of blood products and necrosis [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
      <p>Multiple studies on angiosarcomas have reported the lack of association between histological appearance or grade with survival [<xref ref-type="bibr" rid="CR20">20</xref>]. It appears that small tumor size (&lt;5&#xA0;cm) exclusively favors a better prognosis [<xref ref-type="bibr" rid="CR20">20</xref>]. A multivariate analysis of 55 adult patients with cutaneous and solid-organ angiosarcomas reported mitotic count, tumor size, and mode of treatment as independent favorable prognostic factors [<xref ref-type="bibr" rid="CR9">9</xref>]. Ultimately, early detection and prompt surgical management is the best approach to prevent splenic rupture, which yields the best chance for survival. Splenectomy prior to splenic rupture has been reported to offer a survival advantage with a mean survival time of 14.4&#xA0;months versus 4.4&#xA0;months after rupture [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p>The prognosis for patients with PSA is grim. In the two major case series that examined the behavior of PSA, the overwhelming majority of patients presented with advanced disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The 6-month overall survival after diagnosis is less than 25%. In the pediatric population, survival has been reported from less than 1&#xA0;month to 16&#xA0;years (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). The majority (69 to 100%) of patients with PSA present with metastasis, most commonly to the lungs (78%), liver (63%), bone (31%), and lymph nodes (27%) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. These statistics highlight the importance of early surgical intervention in an attempt to achieve long-term disease-free survival [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p>Owing to the rarity of PSA in the pediatric population, the choice of treatment regimen on this particular case was based on the adult angiosarcoma literature. Case reports in adults, while lacking large cohorts of patients, seem to indicate that patients with angiosarcoma respond to gemcitabine and docetaxel, or to other taxanes [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The combination regimen of gemcitabine and docetaxel has been shown to be effective in the treatment of various malignancies, including non-small cell lung cancer, breast cancer, and advanced uterine leiomyosarcoma [<xref ref-type="bibr" rid="CR24">24</xref>&#x2013;<xref ref-type="bibr" rid="CR26">26</xref>]. A phase II trial also showed efficacy of this regimen in various metastatic soft tissue sarcomas in adults when compared with gemcitabine alone [<xref ref-type="bibr" rid="CR27">27</xref>], and, albeit scarce, there is some evidence to suggest that this combination is effective in pediatric soft tissue sarcomas [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p>
      <p>A retrospective review conducted by Leu and colleagues examined 35 patients with bone and soft tissue sarcomas, including four patients with angiosarcoma [<xref ref-type="bibr" rid="CR25">25</xref>]. Some patients had previously received chemotherapy, mainly with doxorubicin and/or ifosfamide - a combination often used as first-line therapy in various soft tissue sarcomas - and some received gemcitabine and docetaxel due to the toxicity of the doxorubicin/ifosfamide regimen. Of the angiosarcoma patients, two had a complete response to therapy, one had partial response, and one had stable disease. The patients who had a complete response were chemotherapy-na&#xEF;ve while the others were not.</p>
      <p>Additional clinical trials have demonstrated the efficacy of other taxanes at treating angiosarcomas. Penel and colleagues enrolled 30 patients with metastatic or unresectable angiosarcomas in a Phase II clinical trial examining the efficacy and toxicity of weekly paclitaxel [<xref ref-type="bibr" rid="CR22">22</xref>]. Eight patients had locally advanced unresectable disease; 22 patients had metastatic disease. On this regimen of weekly paclitaxel, the non-progression rate was 74% at 2&#xA0;months and 42% at 4&#xA0;months. Overall survival was 56%, 38%, and 21% at 6, 12, and 18&#xA0;months, respectively. Of interest, after weekly paclitaxel treatment, three patients with local disease showed a complete histological response that made curative-intent surgery feasible [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
      <p>The seven pediatric patients previously described in the literature with the addition of the patient in this case are listed in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>
[<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR11">11</xref>]. Similar to their adult counterparts, the pediatric patients rarely presented with localized disease, with only one of the eight patients demonstrating disease localized to the spleen. All the rest presented with metastatic disease. Every patient presenting with metastases had liver involvement. Three patients had involvement of other viscera: lung (1), bone (2), bone marrow (1), serosal surfaces (1), and skin (1).</p>
      <p>Two of the eight pediatric patients achieved durable remission. The patient with disease limited to the spleen was treated by splenectomy without adjuvant therapy. The patient described by den Hoed and colleagues presented with splenic rupture and liver metastases [<xref ref-type="bibr" rid="CR6">6</xref>]. She was treated with ifosfamide, vincristine, and actinomycin D for nine cycles with radiographic improvement in the size and number of the liver lesions. After 5&#xA0;months of observation, two lesions increased in size which prompted wide resection with partial hepatectomy: pathology revealing viable tumor. She received three additional cycles of similar chemotherapy and there remained no evidence of disease at 30&#xA0;months. Our patient likewise demonstrated radiographic, as well as pathologic, response to chemotherapy. When the liver lesions were biopsied, they revealed primarily necrosis with small pockets of viable tumor. The lesions in the liver subsequently progressed rapidly while awaiting evaluation for liver transplantation. She never developed involvement of her other viscera. Three other patients with metastatic disease were treated with a combination of splenectomy and chemotherapy. All of them succumbed to their disease with a range of a few weeks to 10&#xA0;months.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusions">
      <title>Conclusion</title>
      <p>PSA is an extremely rare and aggressive neoplasm of the vasculature that has a very poor prognosis. We present an aggressive multidisciplinary approach in a 3-year-old girl with metastatic PSA who was treated with splenectomy, liver metastasectomy, chemotherapy, and an attempt to liver transplantation. This case report and review of the literature reveals that angiosarcoma in children may be chemo-responsive in some cases. However, this case also illustrates that, in patients with gross disease, surgical extirpation of the primary neoplasm and all metastases is necessary to achieve durable remission. Furthermore, this case underscores the importance of an aggressive multi-disciplinary team approach in these complicated cases aiming for a cure.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient&#x2019;s family for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>CT</term>
            <def>
              <p>computed tomography</p>
            </def>
          </def-item>
          <def-item>
            <term>MRI</term>
            <def>
              <p>magnetic resonance imaging</p>
            </def>
          </def-item>
          <def-item>
            <term>PSA</term>
            <def>
              <p>primary splenic angiosarcoma.</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>OKS and EK wrote the manuscript. OKS and MS performed the surgery. GB prepared images and wrote the legends. DM prepared the pathology slides and wrote the legends. KH, MS, and JG revised the manuscript. All authors have read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rapkin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Qayed</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brill</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Wasilewski-Masker</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alazraki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Katzenstein</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2012</year>
          <volume>59</volume>
          <fpage>854</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.24101</pub-id>
          <pub-id pub-id-type="pmid">22302783</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langhans</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Pulsating cavernous neoplasm of the spleen with metastatic nodules to the liver</article-title>
          <source>Vichows Arch Pathol Anat</source>
          <year>1879</year>
          <volume>75</volume>
          <fpage>273</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02134657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falk</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Meis</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Primary angiosarcoma of the spleen. A clinicopathologic study of 40 cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>1993</year>
          <volume>17</volume>
          <fpage>959</fpage>
          <lpage>970</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199310000-00001</pub-id>
          <pub-id pub-id-type="pmid">8372948</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neuhauser</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Derringer</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Fanburg-Smith</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Miettinen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saaristo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abbondanzo</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases</article-title>
          <source>Mod Pathol</source>
          <year>2000</year>
          <volume>13</volume>
          <fpage>978</fpage>
          <lpage>987</lpage>
          <pub-id pub-id-type="doi">10.1038/modpathol.3880178</pub-id>
          <pub-id pub-id-type="pmid">11007038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hafez</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Trigg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shahidi</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>EF</given-names>
            </name>
          </person-group>
          <article-title>Angiosarcoma of the liver and spleen in an infant</article-title>
          <source>Pediatr Pathol</source>
          <year>1985</year>
          <volume>4</volume>
          <fpage>331</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.3109/15513818509026906</pub-id>
          <pub-id pub-id-type="pmid">3835556</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>den Hoed</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Granzen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Granzen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aronson</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Pauwels</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>de Kraker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Heurn</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
          <article-title>Metastasized angiosarcoma of the spleen in a 2-year-old girl</article-title>
          <source>Pediatr Hematol Oncol</source>
          <year>2005</year>
          <volume>22</volume>
          <fpage>387</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="doi">10.1080/08880010590964228</pub-id>
          <pub-id pub-id-type="pmid">16020128</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ghione</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Primary angiosarcoma of the spleen</article-title>
          <source>Rass Fisiopatol Clin Ter</source>
          <year>1955</year>
          <volume>27</volume>
          <issue>9</issue>
          <fpage>759</fpage>
          <lpage>792</lpage>
          <pub-id pub-id-type="pmid">13298016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsu</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Ueng</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Jan</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Primary angiosarcoma of the spleen in a child with long-term survival</article-title>
          <source>Pediatr Surg Int</source>
          <year>2007</year>
          <volume>23</volume>
          <fpage>807</fpage>
          <lpage>810</lpage>
          <pub-id pub-id-type="doi">10.1007/s00383-007-1874-1</pub-id>
          <pub-id pub-id-type="pmid">17641924</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kren</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Goncharuk</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Dolezel</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Krenova</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Primary angiosarcoma of the spleen in a child</article-title>
          <source>Med Pediatr Oncol</source>
          <year>2003</year>
          <volume>40</volume>
          <fpage>411</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="doi">10.1002/mpo.10140</pub-id>
          <pub-id pub-id-type="pmid">12692821</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sordillo</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sordillo</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Hajdu</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Primary hemangiosarcoma of the spleen: report of four cases</article-title>
          <source>Med Pediatr Oncol</source>
          <year>1981</year>
          <volume>9</volume>
          <issue>4</issue>
          <fpage>319</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="doi">10.1002/mpo.2950090403</pub-id>
          <pub-id pub-id-type="pmid">7196486</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wick</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Beart</surname>
              <given-names>RW</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Primary nonlymphoreticular malignant neoplasms of the spleen</article-title>
          <source>Am J Surg Pathol</source>
          <year>1982</year>
          <volume>6</volume>
          <fpage>229</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-198204000-00005</pub-id>
          <pub-id pub-id-type="pmid">6285748</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zwi</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Wechsler</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Catovsky</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Splenic angiosarcoma following chemotherapy for follicular lymphoma</article-title>
          <source>Hum Pathol</source>
          <year>1986</year>
          <volume>17</volume>
          <fpage>528</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="doi">10.1016/S0046-8177(86)80044-2</pub-id>
          <pub-id pub-id-type="pmid">3516861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamid</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Lairmore</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Primary splenic angiosarcoma</article-title>
          <source>JSLS</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>431</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="doi">10.4293/108680810X12924466006521</pub-id>
          <pub-id pub-id-type="pmid">21333203</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Navasquez</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Angioblastoma of the spleen with metastases to the liver</article-title>
          <source>J Pathol Bacteriol</source>
          <year>1936</year>
          <volume>42</volume>
          <fpage>651</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.1002/path.1700420310</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Autry</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Weitzner</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Hemangiosarcoma of spleen with spontaneous rupture</article-title>
          <source>Cancer</source>
          <year>1975</year>
          <volume>35</volume>
          <fpage>534</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197502)35:2&lt;534::AID-CNCR2820350236&gt;3.0.CO;2-4</pub-id>
          <pub-id pub-id-type="pmid">1167482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kinoshita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yajima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Naganuma</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Splenic hemangiosarcoma with massive calcification</article-title>
          <source>Abdom Imaging</source>
          <year>1999</year>
          <volume>24</volume>
          <fpage>185</fpage>
          <lpage>187</lpage>
          <pub-id pub-id-type="doi">10.1007/s002619900472</pub-id>
          <pub-id pub-id-type="pmid">10024408</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abbott</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Aguilera</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Gorospe</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>From the archives of the AFIP: primary vascular neoplasms of the spleen: radiologic-pathologic correlation</article-title>
          <source>Radiographics</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>1137</fpage>
          <lpage>1163</lpage>
          <pub-id pub-id-type="doi">10.1148/rg.244045006</pub-id>
          <pub-id pub-id-type="pmid">15256634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozt&#xFC;rk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mutlu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>S&#xF6;nmez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sildiro&#x11F;lu</surname>
              <given-names>HO</given-names>
            </name>
          </person-group>
          <article-title>Primary angiosarcoma of the spleen</article-title>
          <source>Turk J Gastroenterol</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>272</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="pmid">18080928</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Onitsuka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Honda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shiraishi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>MRI of primary spleen angiosarcoma with iron accumulation</article-title>
          <source>J Comput Assist Tomogr</source>
          <year>1992</year>
          <volume>16</volume>
          <fpage>298</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="doi">10.1097/00004728-199203000-00021</pub-id>
          <pub-id pub-id-type="pmid">1545029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holden</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Spaull</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>McKee</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>The histogenesis of angiosarcoma of the face and scalp: an immunohistochemical and ultrastructural study</article-title>
          <source>Histopathology</source>
          <year>1987</year>
          <volume>11</volume>
          <fpage>37</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.1987.tb02607.x</pub-id>
          <pub-id pub-id-type="pmid">3104187</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bui</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Cupissol</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ray-Coquard</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Piperno-Neumann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kerbrat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fournier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Taieb</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Isambert</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Peyrade</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chevreau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bompas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brain</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Blay</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study</article-title>
          <source>J Clin Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>5269</fpage>
          <lpage>5274</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.17.3146</pub-id>
          <pub-id pub-id-type="pmid">18809609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trent</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Formiga</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Primary splenic angiosarcoma: prolonged efficacy of gemcitabine plus docetaxel combination chemotherapy</article-title>
          <source>Cancer Therapy</source>
          <year>2008</year>
          <volume>6</volume>
          <fpage>755</fpage>
          <lpage>758</lpage>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hensley</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas</article-title>
          <source>Curr Opin Oncol</source>
          <year>2010</year>
          <volume>22</volume>
          <fpage>356</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="doi">10.1097/CCO.0b013e32833aafef</pub-id>
          <pub-id pub-id-type="pmid">20520541</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leu</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Ostruszka</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Shewach</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zalupski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sondak</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Biermann</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Couwlier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Palazzolo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>1706</fpage>
          <lpage>1712</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2004.08.043</pub-id>
          <pub-id pub-id-type="pmid">15117993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spiridonidis</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Laufman</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rhodes</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nicol</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies</article-title>
          <source>J Clin Oncol</source>
          <year>1998</year>
          <volume>16</volume>
          <fpage>3866</fpage>
          <lpage>3873</lpage>
          <pub-id pub-id-type="pmid">9850032</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maki</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Wathen</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Priebat</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Okuno</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Samuels</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fanucchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Harmon</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Schuetze</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Reinke</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Thall</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Hensley</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration Study 002</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>2755</fpage>
          <lpage>2763</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2006.10.4117</pub-id>
          <pub-id pub-id-type="pmid">17602081</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mora</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>CO</given-names>
            </name>
            <name>
              <surname>Parareda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Torres</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>723</fpage>
          <lpage>729</lpage>
          <pub-id pub-id-type="doi">10.1097/MPH.0b013e3181b2598c</pub-id>
          <pub-id pub-id-type="pmid">19727011</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
